BACKGROUND: The main aim of this study was to examine the relationship between dopamine transporter (DAT) binding in the striatum in individuals with and without attention-deficit/hyperactivity disorder (ADHD), attending to the 3'-untranslated region of the gene (3'-UTR) and intron8 variable number of tandem repeats (VNTR) polymorphisms of the DAT (SLC6A3) gene. METHODS: Subjects consisted of 68 psychotropic (including stimulant)-naïve and smoking-naïve volunteers between 18 and 55 years of age (ADHD n = 34; control subjects n = 34). Striatal DAT binding was measured with positron emission tomography with 11C altropane. Genotyping of the two DAT (SLC6A3) 3'-UTR and intron8 VNTRs used standard protocols. RESULTS: The gene frequencies of each of the gene polymorphisms assessed did not differ between the ADHD and control groups. The ADHD status (t = 2.99; p<.004) and 3'-UTR of SLC6A3 9 repeat carrier status (t = 2.74; p<.008) were independently and additively associated with increased DAT binding in the caudate. The ADHD status was associated with increased striatal (caudate) DAT binding regardless of 3'-UTR genotype, and 3'-UTR genotype was associated with increased striatal (caudate) DAT binding regardless of ADHD status. In contrast, there were no significant associations between polymorphisms of DAT intron8 or the 3'-UTR-intron8 haplotype with DAT binding. CONCLUSIONS: The 3'-UTR but not intron8 VNTR genotypes were associated with increased DAT binding in both ADHD patients and healthy control subjects. Both ADHD status and the 3'-UTR polymorphism status had an additive effect on DAT binding. Our findings suggest that an ADHD risk polymorphism (3'-UTR) of SLC6A3 has functional consequences on central nervous system DAT binding in humans.
BACKGROUND: The main aim of this study was to examine the relationship between dopamine transporter (DAT) binding in the striatum in individuals with and without attention-deficit/hyperactivity disorder (ADHD), attending to the 3'-untranslated region of the gene (3'-UTR) and intron8 variable number of tandem repeats (VNTR) polymorphisms of the DAT (SLC6A3) gene. METHODS: Subjects consisted of 68 psychotropic (including stimulant)-naïve and smoking-naïve volunteers between 18 and 55 years of age (ADHD n = 34; control subjects n = 34). Striatal DAT binding was measured with positron emission tomography with 11C altropane. Genotyping of the two DAT (SLC6A3) 3'-UTR and intron8 VNTRs used standard protocols. RESULTS: The gene frequencies of each of the gene polymorphisms assessed did not differ between the ADHD and control groups. The ADHD status (t = 2.99; p<.004) and 3'-UTR of SLC6A3 9 repeat carrier status (t = 2.74; p<.008) were independently and additively associated with increased DAT binding in the caudate. The ADHD status was associated with increased striatal (caudate) DAT binding regardless of 3'-UTR genotype, and 3'-UTR genotype was associated with increased striatal (caudate) DAT binding regardless of ADHD status. In contrast, there were no significant associations between polymorphisms of DAT intron8 or the 3'-UTR-intron8 haplotype with DAT binding. CONCLUSIONS: The 3'-UTR but not intron8 VNTR genotypes were associated with increased DAT binding in both ADHDpatients and healthy control subjects. Both ADHD status and the 3'-UTR polymorphism status had an additive effect on DAT binding. Our findings suggest that an ADHD risk polymorphism (3'-UTR) of SLC6A3 has functional consequences on central nervous system DAT binding in humans.
Authors: Thomas J Spencer; Bertha K Madras; Alan J Fischman; Johanna Krause; Christian La Fougère Journal: Am J Psychiatry Date: 2012-06 Impact factor: 18.112
Authors: Paul L Soto; Kristin M Wilcox; Yun Zhou; Anil Kumar; Nancy A Ator; Mark A Riddle; Dean F Wong; Michael R Weed Journal: Neuropsychopharmacology Date: 2012-07-18 Impact factor: 7.853
Authors: Elisabeth M van de Giessen; Maartje M L de Win; Michael W T Tanck; Wim van den Brink; Frank Baas; Jan Booij Journal: J Nucl Med Date: 2008-12-17 Impact factor: 10.057
Authors: Barbara Franke; Alejandro Arias Vasquez; Stefan Johansson; Martine Hoogman; Jasmin Romanos; Andrea Boreatti-Hümmer; Monika Heine; Christian P Jacob; Klaus-Peter Lesch; Miguel Casas; Marta Ribasés; Rosa Bosch; Cristina Sánchez-Mora; Núria Gómez-Barros; Noèlia Fernàndez-Castillo; Mònica Bayés; Anne Halmøy; Helene Halleland; Elisabeth T Landaas; Ole B Fasmer; Per M Knappskog; Angelien J G A M Heister; Lambertus A Kiemeney; J J Sandra Kooij; A Marije Boonstra; Cees C Kan; Philip Asherson; Stephen V Faraone; Jan K Buitelaar; Jan Haavik; Bru Cormand; Josep Antoni Ramos-Quiroga; Andreas Reif Journal: Neuropsychopharmacology Date: 2009-11-04 Impact factor: 7.853
Authors: Nora D Volkow; Gene-Jack Wang; Scott H Kollins; Tim L Wigal; Jeffrey H Newcorn; Frank Telang; Joanna S Fowler; Wei Zhu; Jean Logan; Yeming Ma; Kith Pradhan; Christopher Wong; James M Swanson Journal: JAMA Date: 2009-09-09 Impact factor: 56.272
Authors: Thomas J Spencer; Joseph Biederman; Bertha K Madras; Darin D Dougherty; Ali A Bonab; Elijahu Livni; Peter C Meltzer; Jessica Martin; Scott Rauch; Alan J Fischman Journal: Biol Psychiatry Date: 2007-05-23 Impact factor: 13.382
Authors: Abigail Z Rajala; Ismail Zaitoun; Jeffrey B Henriques; Alexander K Converse; Dhanabalan Murali; Miles L Epstein; Luis C Populin Journal: J Neurophysiol Date: 2014-08-13 Impact factor: 2.714
Authors: Alex J Brewer; David A Nielsen; Catherine J Spellicy; Sara C Hamon; Justin Gingrich; Daisy G Y Thompson-Lake; Ellen M Nielsen; James J Mahoney; Thomas R Kosten; Thomas F Newton; Richard De La Garza Journal: Pharmacogenet Genomics Date: 2015-06 Impact factor: 2.089
Authors: Jonathon R Howlett; Laura Campbell-Sills; Sonia Jain; Steven G Heeringa; Matthew K Nock; Xiaoying Sun; Robert J Ursano; Murray B Stein Journal: J Trauma Stress Date: 2018-11-21
Authors: Mariya V Cherkasova; Nazlie Faridi; Kevin F Casey; Gillian A O'Driscoll; Lily Hechtman; Ridha Joober; Glen B Baker; Jennifer Palmer; Alain Dagher; Marco Leyton; Chawki Benkelfat Journal: Neuropsychopharmacology Date: 2013-12-30 Impact factor: 7.853